About MicuRx
Our company
Our Team
Vision & mission
History
Contact Us
Scientific research
Antibiotic Resistance
Kidney Disease
MicuRx R&D
Publications
Pipeline
Newsroom
Corporate news
Careers
Contact Us
中
In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration
Time:2023-07-25 / View:365 times
Prev:
A Novel Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Expresses Anti-Mycobacterium abscessus Activity In Vitro and In Vivo
Next:
A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects
Back
Close